We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports ...
Affimed N.V. (AFMD) has been on a downward spiral lately with significant selling pressure. After declining 47.1% over the past four weeks, the stock looks well positioned for a trend reversal as it ...
A legitimate question of whether the company would conduct a necessary follow-on offering (or PIPE these days) on this data is out there. The fact that AFMD has not done so yet is a good sign in my ...
The big shareholder groups in Affimed N.V. (NASDAQ:AFMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable ...
Affimed experienced a four-month-long sell-off but has caught a bid following their full-year 2021 financial results, where they laid out a transformative 2022. Affimed expects to have three innate ...
The big shareholder groups in Affimed N.V. (NASDAQ:AFMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable ...
Short interest in AFMD (AFMD) increased during the last reporting period, rising from 580.55K to 928.60K. This put -% of the company's publicly available shares short. Short interest in Corp ...
Affirmed Therapeutics (AFMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results